Emcure Pharmaceuticals expects 20% growth in FY27
Trade Brains · · AI-summarised by FinFlash
Emcure Pharmaceuticals told investors on Wednesday that it expects growth of 20% in the fiscal year ending March 2027, according to a live Indian market blog. The forecast arrived during a mixed morning for domestic healthcare stocks, with the Nifty Pharma gauge up 0.43% by midday while the IT index lagged badly. Sector peers Lupin and Global Health reported quarterly numbers in the same session.
So What?
A 20% growth target sets a high bar for the Indian drugmaker; watch whether analysts lift FY27 estimates to match.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.